Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo ––Rademikibart produced a rapid, ...

Podcasting's origins are globally collaborative, not solely American. Podcasting is maturing in Europe and Africa, and, in ...

Post-quantum key exchange attack research has definitively closed a decade-long security question: five cryptographers proved that MQV-style lattice-based AKE protocols cannot achieve eCK security, ...

Researchers analyzed 236 blood metabolites in 421 children to examine metabolic signatures associated with three dietary ...

Guadalajara is one of the safest and most livable cities in Mexico. But, it’s also one of the worst hotspots for organized ...

BOSTON, Sept. 16, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced ...

Sauce Gardner embraces Colts' blockbuster gamble, aiming to reward the faith shown in him and help lead Indianapolis back to ...

Astronomers have detected extreme, never-before-seen behavior from a rare kind of pulsar and stumbled on a surprising link to ...

More than one million genomes helped identify DNA variants linked to extroversion, agreeableness, neuroticism and more.

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and ...

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had ...

Connect expects to report topline data from the ongoing Phase 2 Seabreeze STAT COPD study (CBP-201-207) of rademikibart for the treatment of acute exacerbations in COPD patients with type 2 ...